Psychiatry and Neurology, Neurology · Pikeville, KY
NPI
1831299346
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
515 N Bypass Rd, Suite 101
Pikeville, KY, 41501
Phone (606) 437-4100
Groups this clinician bills Medicare through
Medicare paid, 2024
$94K
4,228 services
Medicare patients, 2024
384
Average age 68
Drug cost, 2024
$1.2M
6,766 prescriptions
Company payments, 2025
$7,687
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sujata R Gutti was code 99213 (office e&m - established), 385 times for 184 patients. In total Sujata R Gutti billed 4,228 services in 19 codes, and Medicare paid $94K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-07-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 385 | 184 | $58.26 | $22K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 213 | 51 | $0.68 | $146 |
| 95886 Electrical Nerve Conductivity | Office | 176 | 96 | $67.66 | $12K |
| 99204 Office E&M - New | Office | 83 | 83 | $115.08 | $9,552 |
| 95816 Neurologic | Facility | 71 | 68 | $40.70 | $2,890 |
| 20552 Musculoskeletal | Office | 55 | 41 | $33.28 | $1,831 |
| 95912 Electrical Nerve Conductivity | Office | 49 | 49 | $166.84 | $8,175 |
| 95816 Neurologic | Office | 34 | 34 | $261.85 | $8,903 |
| 95819 Neurologic | Facility | 30 | 29 | $38.58 | $1,157 |
| 95822 Neurologic | Facility | 26 | 26 | $39.81 | $1,035 |
| 95911 Electrical Nerve Conductivity | Office | 23 | 23 | $152.79 | $3,514 |
| 95909 Electrical Nerve Conductivity | Office | 18 | 18 | $80.55 | $1,450 |
| 99214 Office E&M - Established | Office | 17 | 17 | $77.48 | $1,317 |
| 20553 Musculoskeletal | Office | 16 | 15 | $38.63 | $618 |
By year: 2022 $129K for 4,718 services; 2023 $100K for 4,350 services; 2024 $94K for 4,228 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sujata R Gutti prescribed most often to Medicare patients was Pregabalin, with 563 prescriptions and refills. In total Sujata R Gutti wrote 6,766 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pregabalin Generic | 563 | 565 | 97 | $6,268 |
| Amitriptyline Hcl Generic | 492 | 531 | 88 | $2,891 |
| Duloxetine Hcl Generic | 442 | 487 | 97 | $4,320 |
| Primidone Generic | 326 | 422 | 60 | $3,817 |
| Rizatriptan Rizatriptan Benzoate | 319 | 332 | 97 | $8,176 |
| Gabapentin Generic | 298 | 307 | 61 | $1,731 |
| Levetiracetam Generic | 283 | 346 | 46 | $4,875 |
| Topiramate Generic | 274 | 306 | 59 | $1,470 |
| Meloxicam Generic | 271 | 302 | 98 | $606 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 268 | 325 | 41 | $3,214 |
| Donepezil Hcl Generic | 240 | 366 | 47 | $2,015 |
| Memantine Hcl Generic | 170 | 226 | 29 | $2,579 |
| Oxcarbazepine Generic | 165 | 202 | 31 | $11K |
| Nortriptyline Hcl Generic | 160 | 178 | 46 | $915 |
| Ubrelvy Ubrogepant | 153 | 155 | 33 | $173K |
Brand drugs: 728 claims; generic drugs: 6,017 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sujata R Gutti $7,687 ($7,687 in general payments such as food, travel and fees) from 24 companies. The largest payer was Abbvie Inc. with $5,843.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 32 | $5,843 |
| Biogen, Inc. BIIB | 25 | $489 |
| Vanda Pharmaceuticals Inc. VNDA | 12 | $188 |
| Novartis Pharmaceuticals Corporation NVS | 8 | $187 |
| Pfizer Inc. PFE | 9 | $160 |
| ANI Pharmaceuticals, Inc. ANIP | 10 | $144 |
| Eisai Inc. 4523.T | 6 | $116 |
| Teva Pharmaceuticals USA, Inc. TEVA | 3 | $75.24 |
| Lundbeck LLC | 3 | $66.98 |
| Jazz Pharmaceuticals Inc. JAZZ | 3 | $65.6 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.